The invention relates to a cellular microcompartment comprising successively, organized around a lumen, at least one layer of pluripotent cells, an extracellular matrix layer and an outer hydrogel layer. The invention also relates to processes for preparing such cellular microcompartments.

The present invention relates to a cell support including a base material containing a biocompatible substance or a base material having a surface to which the biocompatible substance is imparted, and gelatin particles held by the biocompatible substance of the base material. The cell support can be produced by a method of causing the base material containing a biocompatible substance to hold the gelatin particles. By seeding cells on the cell support and culturing the cells, a cell structure in which a reagent or a drug has been uniformly taken into more cells can be obtained.

Embodiments herein described provide antigen-presenting cell-mimetic scaffolds (APC-MS) and use of such scaffolds to manipulating T-cells. More specifically, the scaffolds are useful for promoting growth, division, differentiation, expansion, proliferation, activity, viability, exhaustion, anergy, quiescence, apoptosis, or death of T-cells in various settings, e.g., in vitro, ex vivo, or in vivo. Embodiments described herein further relate to pharmaceutical compositions, kits, and packages containing such scaffolds. Additional embodiments relate to methods for making the scaffolds, compositions, and kits/packages. Also described herein are methods for using the scaffolds, compositions, and/or kits in the diagnosis or therapy of diseases such as cancers, immunodeficiency disorders, and/or autoimmune disorders.

The present invention relates to a cell-supporting body, including: a base material including a biocompatible substance; and a gelatin particle retained on the base material. The cell-supporting body can be manufactured by a method of retaining a gelatin particle on a base material including a biocompatible substance. By seeding a cell on the cell-supporting body and culturing the cell, a cell structure in which a reagent or an agent is uniformly incorporated into more cells can be obtained.

The present disclosure provides a method of fabricating curvature-defined (C-D) or shape-defined (S-D) concave and convex polydimethylsiloxane (PDMS) surfaces and a method of fabricating C-D or S-D convex and concave gel surfaces for use in cell and tissue culturing and in other surface and interface applications, and provides a method of using C-D or S-D convex and concave surfaces with varying curvatures to direct cell attachment, spreading, and migration.

The present invention relates to a nano-ligand for promoting cell adhesion and differentiation of stem cells and a method of promoting cell adhesion and differentiation of stem cells by using the nano-ligand, and the method of promoting cell adhesion and differentiation of stem cells according to the present invention may temporally and spatially, and reversibly control nano-ligand sliding by applying a magnetic field to a substrate including the nano-ligands, and efficiently control stem cell adhesion and differentiation ex vivo or in vivo through the magnetic-field based on spatiotemporal control.

A cell culture microcarrier bead is proposed. The microcarrier bead comprises a bead body having its surface flecked with plasmonic nanoparticles. In a second aspect, the invention relates to a cell culture reactor, containing a cell culture medium and the proposed microcarrier beads. A third aspect of the invention concerns a method for observing living cells on such microcarrier beads. Yet a further aspect of the invention relates to a method for packing nanoparticles on a carrier body.

Compositions and methods are provided for isolating, manipulating and using for therapeutic and other purposes, mammalian, MHC Class I restricted, antigen-specific regulatory T cells. The regulatory T cells can be characterized as CD8+ cells that specifically suppress the responses of self-reactive and/or pathogenic CD4+ T cells by cytotoxic mechanisms including, without limitation, perform, other components of the perforin/granzyme apoptosis pathway, etc. The regulatory T cells are antigen-specific, but are not activated by the same antigen as the self-reactive and/or pathogenic CD4+ T cells. In humans the regulatory T cells express inhibitory KIR proteins, e.g. one or more of KIR2DL2, KIR2DL3, and KIR3DL1.

The present disclosure provides methods of producing progenitor cells from induced pluripotent stem cells, wherein the progenitor cells comprise endothelial cells, pericytes, brain microvascular endothelial cells (BMECs), mesenchymal stem cells (MSCs), hematopoietic precursor cells (HPCs), microglia or neural precursor cells (NPCs).

The present invention is directed to a method of producing compositions including embryonic proteins. The method includes culturing cells under hypoxic conditions on a biocompatible surface in vitro. The culturing method produces both soluble and non-soluble fractions, which may be used separately or in combination to obtain physiologically acceptable compositions useful in a variety of medical and therapeutic applications.